{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:46:42Z","timestamp":1793371602448,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nuclear factor erythroid 2-related factor 2 (Nrf2, also called NFE2L2) plays an important role in cancer chemoresistance. However, little is known about the role of Nrf2 in tumor mutation burden and the effect of Nrf2 in modulating DNA mismatch repair (MMR) gene in acute myeloid leukemia (AML). Here we show that Nrf2 expression is associated with tumor mutation burden in AML. Patients with Nrf2 overexpression had a higher frequency of gene mutation and drug resistance. Nrf2 overexpression protected the AML cells from apoptosis induced by cytarabine in vitro and increased the risk of drug resistance associated with a gene mutation in vivo. Furthermore, Nrf2 overexpression inhibited MutS Homolog 2 (MSH2) protein expression, which caused DNA MMR deficiency. Mechanistically, the inhibition of MSH2 by Nrf2 was in a ROS-independent manner. Further studies showed that an increased activation of JNK\/c-Jun signaling in Nrf2 overexpression cells inhibited the expression of the MSH2 protein. Our findings provide evidence that high Nrf2 expression can induce gene instability-dependent drug resistance in AML. This study demonstrates the reason why the high Nrf2 expression leads to the increase of gene mutation frequency in AML, and provides a new strategy for clinical practice.<\/jats:p>","DOI":"10.1038\/s41419-020-03331-x","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T20:03:40Z","timestamp":1610049820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2"],"prefix":"10.1038","volume":"12","author":[{"given":"Ping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"3331_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3331_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner, H. E. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"3331_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/MOH.0000000000000490","volume":"26","author":"AS Mims","year":"2019","unstructured":"Mims, A. S. & Blum, W. Progress in the problem of relapsed or refractory acute myeloid leukemia. Curr. Opin. Hematol. 26, 88\u201395 (2019).","journal-title":"Curr. Opin. Hematol."},{"key":"3331_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-020-01565-3","volume":"39","author":"JE Jang","year":"2020","unstructured":"Jang, J. E. et al. PERK\/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells. J. Exp. Clin. Canc. Res. 39, 66 (2020).","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"3331_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41392-019-0073-6","volume":"4","author":"Y Lv","year":"2019","unstructured":"Lv, Y. et al. The antimicrobial peptide PFR induces necroptosis mediated by ER stress and elevated cytoplasmic calcium and mitochondrial ROS levels: cooperation with Ara-C to act against acute myeloid leukemia. Signal Transduct Target Ther. 4, 38 (2019).","journal-title":"Signal Transduct Target Ther."},{"key":"3331_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet, C. & Jordan, M. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9, 790\u2013803 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3331_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.320","volume":"4","author":"L Steinhart","year":"2013","unstructured":"Steinhart, L., Belz, K. & Fulda, S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis. 4, e802 (2013).","journal-title":"Cell Death Dis."},{"key":"3331_CR8","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1038\/leu.2017.130","volume":"31","author":"J Long","year":"2017","unstructured":"Long, J. et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia 31, 2761\u20132770 (2017).","journal-title":"Leukemia"},{"key":"3331_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12983-z","volume":"10","author":"F Caiado","year":"2019","unstructured":"Caiado, F. et al. Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. Nat. Commun. 10, 4986 (2019).","journal-title":"Nat. Commun."},{"key":"3331_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.leukres.2014.11.004","volume":"39","author":"B Xia","year":"2015","unstructured":"Xia, B. et al. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leuk. Res. 39, 92\u201399 (2015).","journal-title":"Leuk. Res."},{"key":"3331_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","volume":"104","author":"P Dumas","year":"2019","unstructured":"Dumas, P. et al. viaHematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib STAT5-and hypoxia-dependent upregulation of AXL. Haematologica 104, 2017\u20132027 (2019).","journal-title":"Haematologica"},{"key":"3331_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/antiox9030193","volume":"9","author":"E Panieri","year":"2020","unstructured":"Panieri, E. et al. Potential applications of NRF2 modulators in cancer therapy. Antioxidants (Basel) 9, 193 (2020).","journal-title":"Antioxidants (Basel)"},{"key":"3331_CR13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/cancers3021605","volume":"3","author":"S Rushworth","year":"2011","unstructured":"Rushworth, S. & Macewan, D. The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. Cancers 3, 1605\u20131621 (2011).","journal-title":"Cancers"},{"key":"3331_CR14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1089\/ars.2016.6841","volume":"27","author":"J Roh","year":"2017","unstructured":"Roh, J., Jang, H., Kim, E. & Shin, D. Targeting of the glutathione, thioredoxin, and Nrf2 antioxidant systems in head and neck cancer. Antioxid. Redox Sign 27, 106\u2013114 (2017).","journal-title":"Antioxid. Redox Sign"},{"key":"3331_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.biopha.2017.10.129","volume":"97","author":"F Jeddi","year":"2018","unstructured":"Jeddi, F. et al. Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer. Biomed. Pharmacother. 97, 286\u2013292 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"3331_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10549-019-05494-4","volume":"179","author":"M Almeida","year":"2020","unstructured":"Almeida, M. et al. The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis. Breast Cancer Res. Treat. 179, 523\u2013532 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"3331_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1756-9966-31-66","volume":"31","author":"L Zhang","year":"2012","unstructured":"Zhang, L. et al. Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2. J. Exp. Clin. Canc. Res. 31, 66 (2012).","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"3331_CR18","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/mc.22615","volume":"56","author":"L Bao","year":"2017","unstructured":"Bao, L. et al. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. Mol. Carcinog. 56, 1543\u20131553 (2017).","journal-title":"Mol. Carcinog."},{"key":"3331_CR19","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.1158\/0008-5472.CAN-06-2298","volume":"66","author":"X Wang","year":"2006","unstructured":"Wang, X., Hayes, J. & Wolf, C. Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res. 66, 10983\u201310994 (2006).","journal-title":"Cancer Res."},{"key":"3331_CR20","doi-asserted-by":"publisher","first-page":"41692","DOI":"10.18632\/oncotarget.6150","volume":"6","author":"M Tung","year":"2015","unstructured":"Tung, M. et al. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. Oncotarget 6, 41692\u201341705 (2015).","journal-title":"Oncotarget"},{"key":"3331_CR21","doi-asserted-by":"crossref","unstructured":"Sengupta, A. et al. Partial impairment of late-stage autophagic flux in murine splenocytes leads to sqstm1\/p62 mediated nrf2-keap1 antioxidant pathway activation and induced proteasome-mediated degradation in malaria. Microb. Pathogenesis 147, 104289 (2020).","DOI":"10.1016\/j.micpath.2020.104289"},{"key":"3331_CR22","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1074\/jbc.M111.312694","volume":"287","author":"S Niture","year":"2012","unstructured":"Niture, S. & Jaiswal, A. Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. J. Biol. Chem. 287, 9873\u20139886 (2012).","journal-title":"J. Biol. Chem."},{"key":"3331_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","volume":"481","author":"CJ Lord","year":"2012","unstructured":"Lord, C. J. & Ashworth, A. The DNA damage response and cancer therapy. Nature 481, 287\u2013294 (2012).","journal-title":"Nature"},{"key":"3331_CR24","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.biochi.2003.10.007","volume":"85","author":"P Karran","year":"2003","unstructured":"Karran, P., Offman, J. & Bignami, M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 85, 1149\u20131160 (2003).","journal-title":"Biochimie"},{"key":"3331_CR25","volume":"7","author":"A Xavier","year":"2019","unstructured":"Xavier, A. et al. Comprehensive mismatch repair gene panel identifies variants in patients with Lynch-like syndrome. Mol. Genet. Genom. Med. 7, e850 (2019).","journal-title":"Mol. Genet. Genom. Med."},{"key":"3331_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/cjp2.120","volume":"5","author":"A McCarthy","year":"2019","unstructured":"McCarthy, A. et al. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J. Pathol. Clin. Res. 5, 115\u2013129 (2019).","journal-title":"J. Pathol. Clin. Res."},{"key":"3331_CR27","doi-asserted-by":"publisher","first-page":"18061","DOI":"10.1074\/jbc.M103451200","volume":"277","author":"O Humbert","year":"2002","unstructured":"Humbert, O. et al. Implication of protein kinase C in the regulation of DNA mismatch repair protein expression and function. J. Biol. Chem. 277, 18061\u201318068 (2002).","journal-title":"J. Biol. Chem."},{"key":"3331_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2174\/1389450119666180110093713","volume":"19","author":"E Pearsall","year":"2018","unstructured":"Pearsall, E., Lincz, L. & Skelding, K. The role of DNA repair pathways in AML chemosensitivity. Curr. Drug Targets 19, 1205\u20131219 (2018).","journal-title":"Curr. Drug Targets"},{"key":"3331_CR29","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"D Li","year":"2012","unstructured":"Li, D. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506\u2013510 (2012).","journal-title":"Nature"},{"key":"3331_CR30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41379-019-0414-6","volume":"33","author":"J Hechtman","year":"2020","unstructured":"Hechtman, J. et al. Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Mod. Pathol. 33, 871\u2013879 (2020).","journal-title":"Mod. Pathol."},{"key":"3331_CR31","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/cancers12071822","volume":"12","author":"D Hyun","year":"2020","unstructured":"Hyun, D. Insights into the new cancer therapy through redox homeostasis and metabolic shifts. Cancers 12, 1822 (2020).","journal-title":"Cancers"},{"key":"3331_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/and.12903","volume":"50","author":"S Gunes","year":"2018","unstructured":"Gunes, S. et al. Association between promoter methylation of MLH1 and MSH2 and reactive oxygen species in oligozoospermic men-A pilot study. Andrologia 50, e12903 (2018).","journal-title":"Andrologia"},{"key":"3331_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177227","volume":"12","author":"S Karathedath","year":"2017","unstructured":"Karathedath, S. et al. Role of NF-E2 related factor 2 (Nrf2) on chemotherapy resistance in acute myeloid leukemia (AML) and the effect of pharmacological inhibition of Nrf2. PloS ONE 12, e0177227 (2017).","journal-title":"PloS ONE"},{"key":"3331_CR34","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3389\/fonc.2019.00754","volume":"9","author":"X Sun","year":"2019","unstructured":"Sun, X., Wang, S., Gai, J., Guan, J. & Li, Q. SIRT5 promotes cisplatin resistance in ovarian cancer by suppressing DNA damage in a ROS-dependent manner via regulation of the Nrf2\/HO-1 pathway. Front. Oncol. 9, 754 (2019).","journal-title":"Front. Oncol."},{"key":"3331_CR35","doi-asserted-by":"publisher","first-page":"101131","DOI":"10.1016\/j.redox.2019.101131","volume":"22","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. Redox Biol. 22, 101131 (2019).","journal-title":"Redox Biol."},{"key":"3331_CR36","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1182\/blood-2012-04-422121","volume":"120","author":"S Rushworth","year":"2012","unstructured":"Rushworth, S. et al. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-\u03baB and underlies its chemo-resistance. Blood 120, 5188\u20135198 (2012).","journal-title":"Blood"},{"key":"3331_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-017-0317-4","volume":"10","author":"W Wang","year":"2017","unstructured":"Wang, W., Lee, Y. & Lai, Y. PMS2 gene mutation results in DNA mismatch repair system failure in a case of adult granulosa cell tumor. J. Ovarian Res. 10, 22 (2017).","journal-title":"J. Ovarian Res."},{"key":"3331_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fmolb.2020.00122","volume":"7","author":"N Pe\u0107ina-\u0160laus","year":"2020","unstructured":"Pe\u0107ina-\u0160laus, N., Kafka, A., Salamon, I. & Bukovac, A. Mismatch repair pathway, genome stability and cancer. Front. Mol. Biosci. 7, 122 (2020).","journal-title":"Front. Mol. Biosci."},{"key":"3331_CR39","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/nm.2430","volume":"17","author":"B Diouf","year":"2011","unstructured":"Diouf, B. et al. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med. 17, 1298\u20131303 (2011).","journal-title":"Nat. Med."},{"key":"3331_CR40","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/cr.2008.14","volume":"18","author":"G Mao","year":"2008","unstructured":"Mao, G. et al. Preferential loss of mismatch repair function in refractory and relapsed acute myeloid leukemia: potential contribution to AML progression. Cell Res. 18, 281\u2013289 (2008).","journal-title":"Cell Res."},{"key":"3331_CR41","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-15-1018","volume":"15","author":"N Warfel","year":"2016","unstructured":"Warfel, N., Sainz, A., Song, J. & Kraft, A. PIM kinase inhibitors kill hypoxic tumor cells by reducing Nrf2 signaling and increasing reactive oxygen species. Mol. Cancer Ther. 15, 1637\u20131647 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"3331_CR42","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.leukres.2015.02.009","volume":"39","author":"X Lin","year":"2015","unstructured":"Lin, X. et al. Heme oxygenase-1 suppresses the apoptosis of acute myeloid leukemia cells via the JNK\/c-JUN signaling pathway. Leuk. Res. 39, 544\u2013552 (2015).","journal-title":"Leuk. Res."},{"key":"3331_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232635","volume":"15","author":"T Koshizuka","year":"2020","unstructured":"Koshizuka, T. & Inoue, N. Activation of c-Jun by human cytomegalovirus UL42 through JNK activation. PloS ONE 15, e0232635 (2020).","journal-title":"PloS ONE"},{"key":"3331_CR44","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/leu.2016.329","volume":"31","author":"C Zhou","year":"2017","unstructured":"Zhou, C. et al. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia 31, 1196\u20131205 (2017).","journal-title":"Leukemia"},{"key":"3331_CR45","doi-asserted-by":"publisher","first-page":"37469","DOI":"10.1074\/jbc.M006990200","volume":"275","author":"S Scherer","year":"2000","unstructured":"Scherer, S. et al. p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J. Biol. Chem. 275, 37469\u201337473 (2000).","journal-title":"J. Biol. Chem."},{"key":"3331_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-35","volume":"12","author":"C Taylor","year":"2013","unstructured":"Taylor, C., Zheng, Q., Liu, Z. & Thompson, J. Role of p38 and JNK MAPK signaling pathways and tumor suppressor p53 on induction of apoptosis in response to Ad-eIF5A1 in A549 lung cancer cells. Mol. Cancer 12, 35 (2013).","journal-title":"Mol. Cancer"},{"key":"3331_CR47","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3324\/haematol.2018.197749","volume":"104","author":"P Lin","year":"2019","unstructured":"Lin, P. et al. The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes. Haematologica 104, 485\u2013496 (2019).","journal-title":"Haematologica"},{"key":"3331_CR48","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-17-0476","volume":"7","author":"A Schimmer","year":"2017","unstructured":"Schimmer, A. Novel mitochondrial mechanisms of cytarabine resistance in primary AML cells. Cancer Discov. 7, 670\u2013672 (2017).","journal-title":"Cancer Discov."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03331-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03331-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03331-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:40:56Z","timestamp":1669920056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-03331-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["3331"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-03331-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"29 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained in accordance with the Declaration of Helsinki. All experiments with primary samples were approved by the institutional review board of the Affiliated Hospital of Guizhou Medical University (Guiyang, China). The animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee of Guizhou Medical University (Guiyang, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"20"}}